Medinice S.A. has announced the signing of an investment agreement with a Polish fund managed by one of the largest investment fund companies (TFI) in Central and Eastern Europe (“the Investor”). Under the agreement, the fund will acquire Medinice shares worth PLN 12 million, providing the company with long-term financial backing to support its strategic growth.
The new investor—one of the most prominent institutional entities in the European capital market—plans to acquire Medinice shares for PLN 12 million, strengthening the company’s capital base and supporting the continued development of its flagship projects and commercialization processes. The entry of such a significant institutional investor confirms Medinice’s credibility and international growth potential.
“Securing such an important institutional investor is a key milestone for Medinice on the path to global exposure of our projects. Long-term financing enhances our ability to pursue ambitious development and sales goals. At the same time, Medinice continues intensive work on the commercialization of CoolCryo and PacePress – we are currently in talks with global industry players interested in potentially acquiring our technologies,” said Sanjeev Choudhary, CEO of Medinice S.A.
The involvement of the new investor enables the company to focus its efforts on expanding its product portfolio, including flagship projects such as CoolCryo® (an innovative cardiac cryoablation technology), PacePress® (a device that reduces the risk of hematoma following CIED procedures), and AtriClamp® (a clip for left atrial appendage closure). These solutions are in advanced stages of research and development and show strong commercial potential, both in terms of scalability and economic benefits. Recent company milestones include the completion of a clinical study for PacePress® and the submission of a 510(k) application to the U.S. FDA for CoolCryo®.
“Having a major institutional fund among our shareholders not only strengthens our long-term capital stability but also increases our strategic flexibility. It provides a solid foundation for further value growth and accelerates expansion into key markets through the commercialization of our flagship technologies,” added Piotr Łoziński, CFO of Medinice S.A.
Recently, the company also signed a letter of intent with NovelBeam, a global medical technology company, focused on developing additional applications of the CoolCryo technology in robotics and minimally invasive cardiac surgery. The Management Board believes that the commercialization of CoolCryo’s current use, followed by its expansion into robotic applications, will drive further innovation and bring breakthrough medical technologies to the market.
Medinice S.A.’s strategy focuses on developing and commercializing innovative solutions in cardiac surgery and cardiology on global markets, leveraging the expertise of its team and the support of long-term investors such as the newly joined institutional fund.
Source: CEO.com.pl – Medinice secures PLN 12 million investment for CoolCryo and PacePress projects
